On November 1, 2022 Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, reported the company will release its third quarter 2022 financial results and provide a business update on Friday, November 11, 2022 at 8:00 am Eastern Time (Press release, Chemomab, NOV 1, 2022, View Source [SID1234622671]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the event, Chemomab’s management team will review third quarter 2022 performance, discuss recent and upcoming developments and conduct a live question-and-answer session.

A replay of the call will be available on Chemomab’s website for 90 days at www.chemomab.com.

Live Webcast and Conference Call at 8:00 am Eastern Time, Friday, November 11, 2022
Click this Webcast link to access the live webcast or replay.

The live webcast and replay can also be accessed at the News & Events section of the Investors page on the Chemomab website at investors.chemomab.com/events.

Please call 5-10 minutes before the scheduled start time, enter the conference passcode and ask the operator for the Chemomab conference call.

On November 1, 2022 Bio-Techne Corporation (NASDAQ: TECH) reported that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2022 (Press release, Bio-Techne, NOV 1, 2022, View Source [SID1234622670]). The quarterly dividend will be payable November 28, 2022, to all common shareholders of record on November 14, 2022. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bio-Techne also announced today that its board of directors has approved and declared a four-for-one split of Bio-Techne’s common stock in the form of a stock dividend to make stock ownership more accessible to employees and investors. Each stockholder of record on November 14, 2022 will receive a dividend of three additional shares of common stock for each then-held share, to be distributed after close of trading on November 29, 2022. Trading will begin on a stock split-adjusted basis on November 30, 2022.

On November 1, 2022 Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (the Company), reported that it has issued 32,636,476 new registered shares at a nominal value of CHF 0.01 each to Addex Pharma SA, its 100% wholly-owned subsidiary (Press release, Addex Therapeutics, NOV 1, 2022, View Source [SID1234622669]). The new shares, issued from the Company’s authorized capital, are listed on the SIX Swiss Exchange. The transaction has been executed to provide the Group with additional future financing flexibility. The total number of issued shares increased to 97,909,428 at a nominal value of CHF 0.01 each, whilst the outstanding shares remain unchanged.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Swiss Takeover Board Decision
Upon completion of the above-described capital increase, Addex Pharma SA exceeded the offer threshold of 33 1/3% of the voting rights of the Company. Within this context, the Company has to publish the decision of the Swiss Takeover Board (the TOB) of August 18, 2022:

"The Takeover Board decides:

Addex Pharma SA is granted an exemption pursuant to Art. 136 para. 1 lit. c of the Financial Market Infrastructure Act (FMIA) from the obligation to make an offer pursuant to Art. 135 FMIA in respect of all listed shares of Addex Therapeutics Ltd in connection with the transaction described in this decision. This exemption from the obligation to make an offer is granted under the condition that (i) Addex Pharma SA reduces its shareholding in Addex Therapeutics Ltd to or below the threshold of 33 1/3% of the share capital in terms of voting rights by March 31, 2023 and that (ii) Addex Pharma SA does not exercise significant influence on the fate of Addex Therapeutics Ltd during the period in which it exceeds the threshold;

Addex Pharma is required to notify the Swiss Takeover Board within five trading days if it exceeds or falls below the threshold of 33.3% of the share capital and voting rights in Addex Therapeutics Ltd.

Addex Therapeutics Ltd is required to publish the provisions of the present decision as well as the reference to the right of objection of qualified shareholders pursuant to Art. 6 and 7 TOO.

This decision will be published on the website of the Swiss Takeover Board following the publication by Addex Therapeutics Ltd in accordance with clause 3 above.

The fees payable by Addex Pharma SA amount to CHF 20,000."

The Company’s Board of Directors has decided not to publish a separate report within the meaning of Article 61 para. 3 lit. a of the Takeover Ordinance.

Shareholders of the Company who have been holding at least 3% of the voting rights of the Company, whether exercisable or not (a "qualified participation"), since the date of publication of the decision, may file an objection against the decision of the TOB. The objection must be filed with the TOB (Stockerstrasse 54, 8002 Zurich; fax: +41 44 283 17 40) within five (5) trading days from the date of publication of the decision. The first trading day after the publication of the decision on the TOB’s website will be the first day of the filing period. The objection must contain a motion, summary reasons and proof of the qualified participation as from the date of the publication of the decision.

On November 1, 2022 Sysmex Inostics Inc., a subsidiary of Japan’s Sysmex Corporation and Baltimore-based biotechnology firm and CLIA-certified lab, reported that it will exhibit at the Association of Molecular Pathologist (AMP) 2022 Annual Meeting & Expo in Phoenix Arizona from November 3, 2022, through November 5, 2022 (Press release, Sysmex Inostics, NOV 1, 2022, View Source [SID1234622668]). The company will exhibit at booth 701 and take meetings in Expo Hall room seven.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sysmex Inostics will unveil its new website, developed with the award-winning creative agency TRAINA, which echoes Sysmex Inostics’ efforts to deliver intelligent, scientific solutions with a human-centric focus on the boundless potential of every patient.

"As a world-class CLIA lab and liquid biopsy provider, we employ innovative diagnostic tools to fight life shattering diseases. We believe in enhancing every phase of a patient’s journey, from helping bring life-saving drugs to market and expanding treatment options, to giving patients the tools and information they need to live the fullest life possible," said Sysmex Inostics, CEO, Shinichi Sato.

"Our team is committed to changing outcomes for the better. We understand every molecule counts, every decision counts and every patient counts," concluded Sato.

Sysmex Inostics helped pave the way to personal, accurate treatment of devasting diseases through its ultra-sensitive liquid biopsy and biomarker analysis. By empowering actionable molecular discoveries with its next generation sequencing Plasma-Safe-SeqS technology tests and in the past with its venerable OncoBEAM technology, the company has played a significant role in solid tumor cancer and Acute Myeloid Leukemia (AML) discoveries serving the pharmaceutical, clinical, and research communities.

Sysmex Inostics has been active in 2022 with several noteworthy accomplishments:

Partnered with the Foundation of the National Institute of Health (FNIH) & Commenced New Ultra-Sensitive Leukemia Detection Test
In May, Sysmex Inostics partnered with FNIH to discover new modalities to detect and monitor AML Minimal Residual Disease (MRD) which has one of the worst cancer outcomes at a 31 percent 5-year relative survival rate.1

At the same time, Sysmex Inostics began to offer its AML-SEQ CLIA-validated testing service, a focused panel to detect mutations of the three most prevalent genes found in AML. The new test rounds out the company’s offerings with a less expensive test compared to the broader AML-MRD-SEQ for the detection of MRD in 68 regions across 20 genes launched in October 2021.

Launched Head & Neck Cancer CLIA Validated Testing Service
In February, Sysmex Inostics launched its Head & Neck Cancer CLIA-validated testing service, HNSCC sequencing, for cancers that are HPV-negative and driven by mutations in key genes. This test is complementary to the company’s HPV-SEQ service which can identify, quantify, and track HPV 16/18.

On November 1, 2022 MannKind Corporation (Nasdaq: MNKD) reported that it will release its 2022 third quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 9:00 AM (Eastern Time) on Tuesday, November 8, 2022 (Press release, Mannkind, NOV 1, 2022, View Source [SID1234622667]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder.

Those interested in listening to the conference call live via the Internet may do so by visiting the Company’s website at View Source under Events & Presentations.